Evidence map›Paper›PMID 26198225›Full record

ArticleInternational journal of molecular sciences2015

Structural Insights into the Molecular Design of Flutolanil Derivatives Targeted for Fumarate Respiration of Parasite Mitochondria.

Daniel Ken Inaoka, Tomoo Shiba, Dan Sato, Emmanuel Oluwadare Balogun, Tsuyoshi Sasaki, Madoka Nagahama, Masatsugu Oda, Shigeru Matsuoka, Junko Ohmori, Teruki Honma and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Article
  3. Triclabendazole disrupts mitochondrial electron transportAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Synthesis, Anthelmintic Activity, and Mechanism of Action of 5-Aryl-1Journal of agricultural and food chemistry · 2025
    Article
  6. Article
  7. TheInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Design, Synthesis, and Antifungal Activity ofMolecules (Basel, Switzerland) · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Hypoxia Effects onPathogens (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Article
  20. Dual inhibition of theFrontiers in veterinary science · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Daniel Ken InaokaDepartment of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. danielken@m.u-tokyo.ac.jp.
Tomoo ShibaDepartment of Applied Biology, Graduate School of Science Technology, Kyoto Institute of Technology, Kyoto 606-8585, Japan. tshiba@kit.ac.jp.
Dan SatoDepartment of Applied Biology, Graduate School of Science Technology, Kyoto Institute of Technology, Kyoto 606-8585, Japan. dsato@kit.ac.jp.
Emmanuel Oluwadare BalogunDepartment of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. balogun1@m.u-tokyo.ac.jp.
Tsuyoshi SasakiDepartment of Applied Biology, Graduate School of Science Technology, Kyoto Institute of Technology, Kyoto 606-8585, Japan. sasaki198603@gmail.com.
Madoka NagahamaDepartment of Applied Biology, Graduate School of Science Technology, Kyoto Institute of Technology, Kyoto 606-8585, Japan. qp.m.324@gmail.com.
Masatsugu OdaResearch Center, Nihon Nohyaku Co., Ltd., 345 Oyamada-cho, Kawachinagano, Osaka 586-0094, Japan. oda-masatsugu@nichino.co.jp.
Shigeru MatsuokaDepartment of Integrated Analytical Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan. matsuokas11@chem.sci.osaka-u.ac.jp.
Junko OhmoriDepartment of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. jnk.ohmori@gmail.com.
Teruki HonmaCenter for Life Science Technologies, RIKEN, Tsurumi, Yokohama 230-0045, Japan. honma.teruki@riken.jp.
Masayuki InoueDepartment of Integrated Analytical Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan. inoue@mol.f.u-tokyo.ac.jp.
Kiyoshi KitaDepartment of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. kitak@m.u-tokyo.ac.jp.
Shigeharu HaradaDepartment of Applied Biology, Graduate School of Science Technology, Kyoto Institute of Technology, Kyoto 606-8585, Japan. harada@kit.ac.jp.
Kyoto Institute of Technology · JPThe University of Tokyo · JPAhmadu Bello University · NGNihon Nohyaku (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies on the respiratory chain of Ascaris suum showed that the mitochondrial NADH-fumarate reductase system composed of complex I, rhodoquinone and complex II plays an important role in the anaerobic energy metabolism of adult A. suum. The system is the major pathway of energy metabolism for adaptation to a hypoxic environment not only in parasitic organisms, but also in some types of human cancer cells. Thus, enzymes of the pathway are potential targets for chemotherapy. We found that flutolanil is an excellent inhibitor for A. suum complex II (IC50 = 0.058 μM) but less effectively inhibits homologous porcine complex II (IC50 = 45.9 μM). In order to account for the specificity of flutolanil to A. suum complex II from the standpoint of structural biology, we determined the crystal structures of A. suum and porcine complex IIs binding flutolanil and its derivative compounds. The structures clearly demonstrated key interactions responsible for its high specificity to A. suum complex II and enabled us to find analogue compounds, which surpass flutolanil in both potency and specificity to A. suum complex II. Structures of complex IIs binding these compounds will be helpful to accelerate structure-based drug design targeted for complex IIs.

Indexed as

Models, MolecularAnilidesAnimalsAscaris suumBenzoquinonesBinding SitesCell RespirationElectron Transport Complex IIEnzyme InhibitorsFumaratesMitochondriaOxidoreductasesParasitesPhosphoenolpyruvate Carboxykinase (ATP)Substrate SpecificitySuccinic AcidAnilidesBenzoquinonesElectron Transport Complex IIEnzyme InhibitorsflutolanilFumaratesOxidoreductasesPhosphoenolpyruvate Carboxykinase (ATP)quinol fumarate reductasequinoneSuccinic Acidantiparasitic agentAscaris suumcomplex IIcrystal structureflutolanilfumarate respirationmitochondriaNADH-fumarate reductase systemstructure-based drug design

Identifiers

PMID26198225
PMCPMC4519900
OpenAlexW1912141589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.